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Metaplastic breast carcinoma (MBC) is a rare type of breast carcinoma that has
heterogenous histological elements admixed with adenocarcinoma. MBC differs
from typical adenocarcinomas in several pathologic and clinical aspects. 
MBC is mainly manifested by a microscopic pattern of spindle cell carcinoma
or extensive squamous or pseudosarcomatous metaplasia.1 With regards to non-
ductal components, MBC is often pathologically subdivided into several distinct
subtypes, which include squamous, spindle cell, matrix-producing, carcinosar-
coma, etc.2-6 Because of the rarity of these tumors, the pathogenesis is still unknown.
The clinicopathologic features are characterized by larger tumor size and lesser
lymph node involvement with or without poorer clinical outcomes than those seen
with typical breast cancer.7,8 It has been reported that the risk of tumor recurrence
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Purpose: Metaplastic breast carcinoma (MBC) is rare. Its clinicopathologic features
and prognosis are uncertain. The aim of this study was to evaluate the clinicopathol-
ogic characteristics and outcomes in comparison with invasive ductal carcinoma
(IDC). Materials and Methods: We reviewed the data of 29 patients with MBC
and 4,851 patients with IDC, who received surgery at Yonsei University Severance
Hospital between 1980 and 2008. Various clinicopathologic features, recurrence
free, and overall survival were investigated and compared to each other. Results:
Stage IV cases at diagnosis were more common in MBC (10.3%) than in IDC
(0.9%). The incidence rates of triple negative breast cancer (TNBC) were
significantly higher in MBC (84.0%) than in IDC (20.1%). Larger tumors (>2 cm)
and lower tendency of axillary metastasis were frequently observed in MBC. Only
one of 24 preoperative core needle biopsies (CNB) correctly diagnosed MBC. There
was no significant difference in survival between the two groups. Conclusion: MBC
was characterized by a higher incidence of TNBC, larger tumor size, and lower
tendency of axillary metastasis, and was difficult to diagnose with CNB. Although
the incidence of stage IV disease at diagnosis was higher in MBC, the survival rates
of stage I-III were comparable to those of IDC.  
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of MBC is relatively higher than typical breast cancer;
however, this remains controversial.9,10
Recently, MBC has been issued because this neoplasm
is usually characterized by a lack of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth factor receptor-2 (HER2/neu) over-expression,
which is called ‘triple negativity’. Hormone receptor ex-
pression in MBC is reported only in 0-26% of cases3,11 and
triple negative breast cancer has been known to be resistant
to conventional endocrine therapy for hormone receptors
positive breast cancer or targeted therapies such as trastu-
zumab for HER2/neu over-expressing breast cancers.12-16
The purpose of this study was to investigate the clinico-
pathologic characteristics and outcomes of MBC in com-
parison with invasive ductal carcinoma.
We retrospectively reviewed the data of 29 cases with
MBC and 4,851 cases with invasive ductal carcinoma
(IDC), who received surgery at Yonsei University Seve-
rance Hospital, between 1980 and 2008. The incidence
rates of MBC were calculated using data of 6,313 cases of
the Breast Cancer Registry of Yonsei University Severance
Hospital, between 1974 and 2008. Three MBC and 43
IDC patients were revealed as cases with distant metastasis
at diagnosis.
To compare the clinicopathologic features between the
two groups, the following variables were documented: age,
subtype, tumor size, nodal status, status of ER and PR,
HER2/neu over-expression, operation type, decade of
operation, systemic treatment status, preoperative biopsy
results, and locoregional or systemic recurrence events. 
The cut off value for ER and PR positive was more than
10% staining in immunohistochemisty. Before 1994, the
level of the hormone receptor was measured by ligand
binding assays, and the positive level was defined as over
3 fmol/mg protein at that time. An immunohistochemistry
score of three positive was defined as positive for HER2/
neu overexpression.
Five years recurrence free survival (RFS) and overall
survival (OS) rates in both groups were calculated and
compared. The RFS rate considered locoregional recur-
rence and distant recurrence as events, and the events of
overall survival were death with any cause. We excluded
the cases with distant metastasis at diagnosis in survival
analysis.
We used student t-test to calculate mean values in con-
tinuous variables and the results were given as mean ±
standard deviation. Pearson’s Chi-square test and Fisher’s
exact test were used for measuring statistical differences in
categorical variables and all statistical tests were two-
sided. The Kaplan-Meier method was used to plot the RFS
and OS rates. Statistical significance was accessed by log-
rank test. p < 0.05 is considered to be a statistically signi-
ficant level. All statistical analysis was performed with
PASW statistics 17.0 (SPSS Inc, Chicago, IL, USA).
All MBC cases were female. Their mean age at diagnosis
was 49 years (range, 28-68), and there were no statistical
differences in mean age between both groups. The positive
rates of ER, PR, and HER2/neu were 3.7%, 7.4%, and
8.0%, respectively, in the MBC cases. The incidence of
triple negative breast cancer (TNBC) in MBC was 84%.
Tumors larger than 2 cm were more frequent in the MBC
group (86.2%) than the IDC group (45.8%, p < 0.001).
However, lymph node involvement was less common in
MBC than IDC (31.0% vs. 46.6%, p = 0.13). There was no
significant difference in operation methods, the rate of
performing neoadjuvant and adjuvant chemotherapy, and
radiation therapy between the groups. Only 20.7% of the
MBC cases were treated with endocrine therapy, which
differed from the IDC group (20.7% vs. 58.6%, p < 0.001).
There were 3 (11.5%) locoregional recurrences and 4
(15.4%) systemic recurrences in the MBC group, and 422
(8.8%) and 816 (17.1%), respectively, in the IDC group. In
terms of recurrence rate, there was no statistical difference
between the two groups. In contrast, the incidence of stage
IV disease at diagnosis was more commonly observed in
MBC compared with IDC (10.3% vs. 0.9%, p = 0.002)
(Table 1).
There were 7 matrix producing, 1 spindle cell, 4 sarco-
matous, 3 squamous, 8 chondroid, and 4 mixed differen-
tiations, and two cases diagnosed in the 1980s without
specified subtypes. 
The incidence rate of the MBC was 0.5% of all breast
cancers treated at our institute. Among 29 MBC cases, 24
cases (82.7%) were diagnosed between 2000 and 2008,
and the incidence rate of MBC significantly increased after
2000 (Table 2).
Twenty-one of 24 patients with MBC between 2000 and
2008 were tentatively diagnosed as invasive ductal carci-
noma with preoperative core needle biopsy and only one
case (4.2%) of them was correctly diagnosed with a preo-
perative core needle biopsy (Table 3).
The median follow-up time of MBC and IDC cases
were 32 and 57 months, respectively. Kaplan-Meier curves
for RFS and OS comparing MBC and IDC are illustrated
in Fig. 1. Five-year RFS rates of MBC and IDC were
81.5% and 84.1%, and OS rates were 93.3% and 89.1%,
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respectively. Comparisons of the groups for recurrence-
free and overall survival rates revealed no statistically signi-
ficant differences (p > 0.05), and RFS and OS with regard
to TNM stage are also not related with histologic type (p >
0.05, data not shown).
MBC is rare and it has been reported that the incidence is
less than 1% of all breast malignancies.8,17,18 In this study,
the incidence of MBC was 0.5%. Interestingly, about 80%
of all cases were diagnosed in the 2000s (0.19% and
0.65% before and after 2000, respectively). The increase of
the diagnosis of MBC was consistent with the previous
study based on the National Cancer Data Base.19 Barnes, et
al.16 also reported a recent increase of MBC and it might be
caused by incomplete tumor descriptions and/or misclassi-
fication in earlier years compared with the later decade, or
by increased recognition of MBC as a distinct breast tumor
subtype according to improved diagnostic accuracy or by a
true rise in incidence. 
As shown in Table 3, only one of 24 was correctly dia-
gnosed MBC with core needle biopsy before surgery,
which suggested that it is difficult to make an accurate dia-
gnosis with core needle biopsy. Since MBC consists of at
least two distinct histologic components, the volume of
samples obtained by core needle biopsy might not be
sufficient to distinguish MBC from common types of breast
cancers, and this analysis is consistent with a previous
study.7
In terms of the incidence of stage IV disease at presen-
tation, 10.3% (3 of 29) of MBC cases were stage IV, which
was much higher than 0.9% (43 of 4,851) of IDC at our
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DISCUSSION
Table 1. Clinicopathological Features between Metaplastic Breast Carcinoma and Invasive Ductal Carcinoma
MBC IDC
p value
n = 29 (%) n = 4,851 (%)
Age 49.7 ± 10.8 48.2 ± 10.2 0.41
ER positive 1 (3.7) 2,585 (64.0) < 0.001
PR positive 2 (7.4) 2,320 (58.4) < 0.001
HER2/neu > 3 positive 2 (8.0) 774 (25.1) 0.06*
TNBC 21 (84.0) 619 (20.1) < 0.001*
Tumor size (cm) 4.6 ± 5.5 2.4 ± 6.5 0.06
Tumor size > 2 cm 25 (86.2) 1,593 (45.8) < 0.001
LN positive 9 (31.0) 2,255 (46.6) 0.13
Neoadjuvant chemotherapy 6 (23.1) 456 (14.4) 0.25*
Operation type 0.39
Partial mastectomy 5 (17.2) 1,247 (25.7)
Total mastectomy 24 (82.8) 3,602 (74.3)
Hormone therapy 6 (20.7) 2,715 (58.6) < 0.001
Adjuvant chemotherapy 22 (75.9) 3,409 (72.2) 0.68
Radiation therapy 11 (37.9) 2,015 (43.6) 0.57
Stage IV at diagnosis 3 (10.3) 43 (0.9) 0.002*
Recurrence pattern
Local 3 (11.5) 422 (8.8) 0.49*
Systemic 4 (15.4) 816 (17.1) 1.0
TNBC, triple negative breast cancer; LN, lymph node.
*Fisher’s exact test.
Table 2. The Incidence of Metaplastic Breast Carcinoma
MBC (%) Others (%)* p value
Before 2000 5 (0.19) 2,629 (99.8)
After 2000 24 (0.65) 3,655 (99.3) 0.005
Total 29 (0.5) 6,284 (99.5)
MBC, metaplastic breast cancer.
*All types of breast malignancies except MBC. 
institute, 2.8% of all registered breast cancers reported by
the Korean Central Cancer Registry (KCCR) and Korea
Breast Cancer Society Registry (KBCS) data,20 and 2.7-
4.9% reported from other previous studies.18,21 The inci-
dence of distant metastasis cases in MBC were reported as
3.3-13.2%.18,22,23 This result might suggest that MBC is more
aggressive than other types of breast cancers and the
incidence of stage IV disease at presentation is more com-
mon. However, because our database only includes data of
patients who received surgical treatment, we must be very
cautious to interpret the current results as a higher rate of
stage IV disease in MBC.
There were six subtypes of MBC in the current study.
Breast cancer with chondroid differentiation and matrix
producing carcinoma were the most common subtypes,
with an incidence of 27.6% and 24.1%, respectively. Des-
cription of the subtypes of MBC varies.2-6,8,23 Subtypes of
MBC were described as matrix-producing carcinoma,
squamous cell carcinoma, spindle cell carcinoma, carcino-
sarcoma, MBC with osteoclastic giant cells, spindle cell
metaplasia, adenosquamous carcinoma, MBC with chon-
droid differentiation, and so on.2-6,16 The molecular analysis
also reported the heterogeneity of MBC.24 The prognostic
significance of the histologic subtypes in MBC is not esta-
blished. Oberman suggested that MBC is considered a
single entity, but Wargotz, et al. implied that subdivision
into multiple histological phenotypes may be related with
prognosis.2-6 Because of the small sample size, we could
not evaluate the prognosis by subtypes. 
MBC is usually regarded as TNBC or basal-like breast
cancer (BLBC),12,14,25,26 and the lower positive rates of ER,
PR, and HER2/neu overexpression in MBC were observed
in numerous studies.7,8,11,16,19,27 TNBC is clinical nomencla-
ture based on hormone receptor and HER2/neu status, and
BLBC is defined by a mRNA expression pattern of an
intrinsic gene set.28,29 In fact, the TNBC clusters with
BLBC, and they are often used as synonyms regardless of
the distinctive clinical and molecular complimentary sets.
Generally, it has been believed that the prognosis of MBC
is relatively poor,7,16,23,30 even though this remains contro-
versial.8,10 Previous studies supported the finding that the
poor outcomes of MBC seemed to be associated with
triple negativity.7 In addition, others reported that MBC is
connected with BLBC for which no specific target therapy
is available, and Weigelt, et al. reported that 95% of MBC
are BLBC.22,31-33 Our analysis found that MBC showed a
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Table 3. Preoperative Pathologic Diagnosis of Metaplastic Breast Carcinoma Cases after 2000
Postop. Dx
p value
MBC (%) IDC (%)
Preop. Dx MBC 1 (4.2) 0 (0)
IBC or DCIS 21 (87.5) 2,466 (93.3) 0.007
Other 2 (8.3)* 176 (6.7)
Total 24 (100) 2,642 (100)
Postop. Dx, postoperative final pathologic diagnosis; MBC, metaplastic breast carcinoma; IDC, invasive ductal carcinoma; Preop. Dx, 
preoperative diagnosis; IBC, invasive breast cancer except MBC; DCIS, ductal carcinoma in situ. 
*One case of suspicious cancer and one case of missing data.
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Fig. 1. Recurrence-free and overall survival according to histologic type of breast cancer in Stage I-III. MBC, metaplastic breast carcinoma; IDC,
invasive ductal carcinoma.
trend toward triple negativity, with less than 10% of ER,
PR, and HER2/neu positivity, and the incidence of TNBC
in MBC is remarka-bly higher than in IDC.
A number of studies have consistently reported that
MBC is usually larger than typical breast cancer at
presentation.7,9,16,19,34 The mean tumor size in our results was
4.6 cm (range, 1.5-31 cm) and the incidence of tumors
larger than 2 cm was 86.2%, which were comparable to
previous reports showing larger tumor sizes in MBC than
in other types.7,9,16,19,34 The axillary node involvement rate of
MBC tended to be lower than that of IDC in this study,
which was consistent with other reports showing that MBC
is usually associated with a lower incidence of axillary
node metastasis, 0-26%, in spite of a larger tumor size than
typical breast cancer.2-4,7,8,16,19,23 The reasons why MBC
shows a lower rate of nodal involvement in spite of larger
tumor size, which may indicate that tumor proliferation
mechanism of MBC is somewhat different from that of a
typical ductal origin tumor, are of interest. A large-scale
transcriptional profiling study revealed that MBC has a
few genes that are related with epithelial-mesenchymal
transition, which may be recognized as a potential mecha-
nism for the progression of malignancy.35 This previous
report is not sufficient to fully explain why MBC shows
larger tumor sizes than typical breast cancer, but it may
offer clues to understand that there are possibilities of
different proliferation mechanisms of MBC compared
with typical ductal origin tumors.
In the survival analysis between the two groups, RFS
and OS according to the histologic type did not show any
statistically significant differences. These findings are
consistent with previous studies that reported comparable
outcomes with matched typical breast cancer and favorable
prognosis.7,8 However, the prognosis of MBC still remains
controversial because a series of reports demonstrated that
MBC showed more aggressive behavior than typical breast
cancer.16,23 In addition, it is of interest that the survival curves
appear that almost all of the MBC recurrences occurred
during the first five years, whereas for IDC, which is pre-
dominantly composed of ER positive patients, the curves
continued to fall over time. There is a possibility that MBC
may show earlier recurrence than IDC; however, the small
size of the events in the MBC group limited further analy-
sis to confirm these results.
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